Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

CEO Mark Goldsmith outlined the company’s late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into ...
The Lancet

Statin safety: when warnings outlive the evidence

More than 30 years after the Scandinavian Simvastatin Survival Study showed that statins save lives, their full public health potential remains unrealised. Statins are underused worldwide, and as a ...
Gut

Rise of prediagnostic molecular profiling in inflammatory bowel disease—can we close the door before the horse has bolted?

Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial ...